Table 3 Surfactant doses received in GLSE and Beractant groups

From: Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial

Characteristic

GLSE (n = 52)

Beractant (n = 46)

p-value

No. of surfactant doses received (including the first IP dose)

   

 1

18 (34.6)

38 (82.6)

 

 2

19 (36.5)

7 (15.2)

<0.001

 ≥3

15 (28.8)

1 (2.2)

 

Mean number of surfactant doses received

1.94 ± 0.8

1.22 ± 0.6

<0.001

Age at second dose (h)

(n = 34)

(n = 8)

 

 Mean ± SD

11.5 ± 5.8

13.6 ± 5.4

0.36

Median (IQR)

9.8 (7.8,13.4)

12.2 (710,16.6)

 

Age at third dose (h)

(n = 15)

(n = 1)

 Mean ± SD

29.0 ± 19.7

19.6

 

Median (IQR)

17.6 (13,47.2)

19.6

 

Mean age at fourth dose (h)

0

(n = 1) 28.2

  1. IP Investigational product